Literature DB >> 31656801

Immune-checkpoint inhibitors in brain metastases from renal cell carcinoma: a battle was lost but not the war.

Giuseppe Lombardi1, Marco Maruzzo1, Giuseppe Minniti2, Marta Padovan1, Mario Caccese1, Vittorina Zagonel1.   

Abstract

Entities:  

Year:  2019        PMID: 31656801      PMCID: PMC6789375          DOI: 10.21037/atm.2019.08.42

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  22 in total

1.  Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Authors:  Ronan Flippot; Cécile Dalban; Brigitte Laguerre; Delphine Borchiellini; Gwénaelle Gravis; Sylvie Négrier; Christine Chevreau; Florence Joly; Lionnel Geoffrois; Sylvain Ladoire; Hakim Mahammedi; Frédéric Rolland; Marine Gross-Goupil; Elise Deluche; Frank Priou; Mathieu Laramas; Philippe Barthélémy; Bérengère Narciso; Nadine Houedé; Stéphane Culine; Stéphane Oudard; Marina Chenot; Florence Tantot; Sylvie Chabaud; Bernard Escudier; Laurence Albiges
Journal:  J Clin Oncol       Date:  2019-06-13       Impact factor: 44.544

Review 2.  Brain metastases.

Authors:  Achal Singh Achrol; Robert C Rennert; Carey Anders; Riccardo Soffietti; Manmeet S Ahluwalia; Lakshmi Nayak; Solange Peters; Nils D Arvold; Griffith R Harsh; Patricia S Steeg; Steven D Chang
Journal:  Nat Rev Dis Primers       Date:  2019-01-17       Impact factor: 52.329

3.  Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Authors:  Lucio Crinò; Giuseppe Bronte; Paolo Bidoli; Paola Cravero; Elisa Minenza; Enrico Cortesi; Marina C Garassino; Claudia Proto; Federico Cappuzzo; Francesco Grossi; Giuseppe Tonini; Maria Giuseppina Sarobba; Graziella Pinotti; Gianmauro Numico; Riccardo Samaritani; Libero Ciuffreda; Antonio Frassoldati; Marco Bregni; Antonio Santo; Francovito Piantedosi; Alfonso Illiano; Filippo De Marinis; Stefano Tamberi; Diana Giannarelli; Angelo Delmonte
Journal:  Lung Cancer       Date:  2019-01-15       Impact factor: 5.705

4.  Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.

Authors:  J Beck; G Procopio; E Bajetta; U Keilholz; S Negrier; C Szczylik; C Bokemeyer; S Bracarda; D J Richel; M Staehler; U P Strauss; S Mersmann; K Burock; B Escudier
Journal:  Ann Oncol       Date:  2011-02-15       Impact factor: 32.976

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 6.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Authors:  Lawrence Fong; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

7.  Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.

Authors:  Prashant Gabani; Benjamin W Fischer-Valuck; Tanner M Johanns; Leonel F Hernandez-Aya; Jesse W Keller; Keith M Rich; Albert H Kim; Gavin P Dunn; Clifford G Robinson; Michael R Chicoine; Jiayi Huang; Christopher D Abraham
Journal:  Radiother Oncol       Date:  2018-06-27       Impact factor: 6.280

8.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

Authors:  Willemijn S M E Theelen; Heike M U Peulen; Ferry Lalezari; Vincent van der Noort; Jeltje F de Vries; Joachim G J V Aerts; Daphne W Dumoulin; Idris Bahce; Anna-Larissa N Niemeijer; Adrianus J de Langen; Kim Monkhorst; Paul Baas
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

9.  Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Authors:  Aly-Khan A Lalani; Kathryn P Gray; Laurence Albiges; Marcella Callea; Jean-Christophe Pignon; Soumitro Pal; Mamta Gupta; Rupal S Bhatt; David F McDermott; Michael B Atkins; G F Vande Woude; Lauren C Harshman; Toni K Choueiri; Sabina Signoretti
Journal:  Oncotarget       Date:  2017-10-23

10.  Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma.

Authors:  An Uche; Chad Sila; Tad Tanoura; James Yeh; Neil Bhowmick; Edwin Posadas; Robert Figlin; Jun Gong
Journal:  Case Rep Urol       Date:  2019-02-13
View more
  2 in total

Review 1.  Second-line treatment in renal cell carcinoma: clinical experience and decision making.

Authors:  Valentina Guadalupi; Giacomo Cartenì; Roberto Iacovelli; Camillo Porta; Giovanni Pappagallo; Riccardo Ricotta; Giuseppe Procopio
Journal:  Ther Adv Urol       Date:  2021-06-18

2.  Musashi1 expression is negatively correlated with numb expression in brain metastases.

Authors:  Yalan Dong; Jianfeng Li; Rongju Liu; Zhenxiang Zhao; Shuaibin Wang; Kai Cui
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.